On this page
Ornithine transcarbamylase deficiency
OTC deficiency is a genetic condition affecting the urea cycle, leading to a build-up of ammonia. It can cause severe symptoms, especially in affected males, and requires lifelong management. Early diagnosis and treatment are crucial to prevent serious health complications.
Available at Jeen Health
Clinical tests that include this
Overview
Ornithine transcarbamylase deficiency (OTC deficiency) is the most common inherited disorder of the urea cycle [PMID:31194348]. The urea cycle is a series of biochemical reactions that take place mainly in the liver, responsible for converting excess nitrogen, in the form of ammonia, into urea. Urea can then be safely excreted from the body via the kidneys. When the ornithine transcarbamylase (OTC) enzyme is deficient or not working correctly, ammonia builds up in the bloodstream, a condition known as hyperammonaemia. Ammonia is highly toxic, particularly to the brain, and can cause significant health problems if not managed.
OTC deficiency affects individuals differently, with symptoms ranging from severe, life-threatening episodes in early infancy to milder, later-onset presentations. The estimated prevalence of OTC deficiency varies, but research suggests it affects between 1 in 14,000 and 1 in 70,000 live births globally [PMID:31194348]. Due to its X-linked inheritance pattern, males are typically more severely affected than females.
Symptoms & clinical features
Symptoms of OTC deficiency can vary widely depending on the severity of the enzyme deficiency and the age of onset. In severely affected newborn males, symptoms often appear within the first few days of life, after protein feeding has begun. These can include poor feeding, vomiting, lethargy, irritability, and seizures. Without prompt treatment, this can rapidly progress to coma and brain damage due to the toxic effects of ammonia on the brain.
In individuals with milder forms, symptoms may not appear until later in childhood or even adulthood. These presentations can be triggered by stress, illness, high-protein meals, or certain medications. Symptoms in later-onset cases might include episodes of confusion, headaches, behavioural changes, intellectual difficulties, or cyclical vomiting. Some affected females who are carriers of the condition may experience mild symptoms, particularly under metabolic stress, but they often remain asymptomatic [PMID:20301386].
Video: Genetics 101
Affected organs
The primary organs affected by OTC deficiency are the brain and the liver. The liver is where the urea cycle primarily takes place, and the dysfunction of the OTC enzyme directly impacts its ability to detoxify ammonia. However, the most significant damage occurs in the brain due to hyperammonaemia.
High levels of ammonia are neurotoxic, meaning they are poisonous to brain cells. This can lead to cerebral oedema (swelling of the brain), which can cause permanent neurological damage, developmental delay, intellectual disability, and in severe cases, coma and death. Other organs can be indirectly affected by the systemic metabolic imbalance, but the neurological consequences are the most critical in OTC deficiency.
Risks & severity
The severity of OTC deficiency is highly variable. Severe forms typically affect newborn males and carry a high risk of life-threatening hyperammonaemic crises, which can lead to profound neurological impairment or death if not rapidly treated. Even with treatment, long-term neurological complications such as developmental delay, learning difficulties, and cerebral palsy are common in those who survive early severe crises.
Individuals with partial OTC enzyme activity may experience milder, later-onset disease. They are still at risk of hyperammonaemic episodes, particularly during illness, surgery, or when consuming high-protein diets. These episodes can also be life-threatening and require emergency intervention. Affected females, even those who are carriers, can experience a spectrum of symptoms from asymptomatic to severe, depending on X-chromosome inactivation patterns. All individuals with OTC deficiency, regardless of severity, face a lifelong risk of metabolic decompensation and require careful monitoring and management.
Genetic causes
Ornithine transcarbamylase deficiency is caused by pathogenic changes in the *OTC* gene. The *OTC* gene provides instructions for making the ornithine transcarbamylase enzyme, which is located in the mitochondria of liver cells. This enzyme plays a crucial role in the urea cycle, specifically converting ornithine and carbamoyl phosphate into citrulline.
The urea cycle is vital for the body's detoxification process, as it removes ammonia, a by-product of protein breakdown. When pathogenic variants occur in the *OTC* gene, the resulting enzyme is either absent or dysfunctional. This leads to a blockage in the urea cycle, causing ammonia to accumulate in the blood to toxic levels [PMID:31194348]. The type of genetic change and its effect on enzyme function often correlate with the severity of the condition.
- OTC ornithine transcarbamylaseThe *OTC* gene provides instructions for making ornithine transcarbamylase, an enzyme vital for the body's urea cycle, which processes excess nitrogen and prevents ammonia accumulation.
Inheritance pattern
OTC deficiency has an X-linked recessive inheritance pattern. The *OTC* gene is located on the X chromosome. Males have one X chromosome and one Y chromosome (XY), so if their single X chromosome carries a pathogenic *OTC* variant, they will typically develop the condition.
Females have two X chromosomes (XX). If one X chromosome carries a pathogenic *OTC* variant, they are considered carriers. Due to a process called X-inactivation (where one of the two X chromosomes in each cell is randomly 'switched off'), carrier females can have varying degrees of functional OTC enzyme activity. This means some carriers might be asymptomatic, while others can experience symptoms ranging from mild to severe, particularly under metabolic stress [PMID:20301386]. A male with OTC deficiency cannot pass the condition to his sons, but all his daughters will be carriers. A female carrier has a 50% chance of passing the pathogenic variant to each child, regardless of sex. If she passes it to a son, he will be affected; if she passes it to a daughter, that daughter will be a carrier.
X-linked recessive: sons of a carrier mother have a 50% chance of being affected. Daughters have a 50% chance of being carriers.
Diagnosis & testing
Diagnosis of OTC deficiency often begins with clinical suspicion, especially in infants presenting with unexplained lethargy, poor feeding, or seizures, or in older individuals with episodes of encephalopathy or vomiting. Initial investigations typically involve blood tests to measure ammonia levels, which will be significantly elevated in affected individuals during a hyperammonaemic crisis. Other blood and urine tests, such as plasma amino acid analysis and urine organic acids, can help differentiate OTC deficiency from other urea cycle disorders or metabolic conditions.
Confirmation of OTC deficiency relies on genetic testing of the *OTC* gene. In the UK, genetic testing for suspected urea cycle disorders, including OTC deficiency, can be accessed through the NHS Genomic Medicine Service following a referral to a clinical genetics service. This falls under specific R-codes for inherited metabolic disorders. Genetic testing can identify pathogenic variants in the *OTC* gene, confirming the diagnosis and allowing for family studies to identify carriers and at-risk relatives [PMID:20301386].
Management & lifestyle
Management of OTC deficiency is complex and lifelong, focusing on preventing hyperammonaemic crises and minimising long-term neurological damage. This typically involves a combination of dietary protein restriction, medications to help remove ammonia, and close monitoring. During an acute hyperammonaemic crisis, emergency treatment is vital, including intravenous ammonia scavengers and sometimes dialysis to rapidly reduce ammonia levels.
Long-term management usually includes a carefully controlled low-protein diet tailored to individual needs by a specialist dietitian. Medications such as sodium phenylbutyrate or carglumic acid may be used to help the body excrete nitrogen waste products. Liver transplantation is a potential treatment option for severe cases, as it provides a source of functional OTC enzyme, but it carries significant risks and is usually considered after other treatments have been exhausted. Individuals with OTC deficiency are typically managed by a multidisciplinary team within the NHS, including metabolic specialists, dietitians, and genetic counsellors [PMID:31194348]. Regular follow-up appointments and prompt treatment during periods of illness are crucial.
UK care pathway
In the UK, individuals suspected of having Ornithine transcarbamylase deficiency are generally referred to a clinical genetics service or a specialist metabolic centre. The NHS Genomic Medicine Service provides diagnostic testing for rare and inherited diseases, including metabolic disorders, under specific R-codes. Clinical geneticists will assess the patient, arrange appropriate genetic testing, and provide a diagnosis. Following diagnosis, patients are typically linked with a specialised metabolic team within the NHS, often including metabolic physicians, specialist nurses, and dietitians, who will coordinate ongoing care and management. Genetic counsellors are available to provide support, explain the inheritance pattern, and discuss implications for family planning and at-risk relatives.
Frequently asked questions
What is ammonia, and why is it dangerous in OTC deficiency?
Ammonia is a toxic waste product created when the body breaks down proteins. In OTC deficiency, the body cannot convert this ammonia into urea, causing it to build up in the blood. High ammonia levels are particularly harmful to the brain, leading to swelling and potential permanent damage or coma.
Can females be affected by OTC deficiency?
Yes, while males are typically more severely affected, females can also experience symptoms of OTC deficiency. Females are often carriers, but due to X-chromosome inactivation, some carrier females can develop symptoms ranging from mild to severe, especially under metabolic stress like illness or high protein intake.
What is a 'hyperammonaemic crisis'?
A hyperammonaemic crisis is a life-threatening episode where ammonia levels in the blood rise very quickly to dangerous levels. This can cause severe symptoms like confusion, vomiting, lethargy, seizures, and lead to coma. Immediate medical attention is essential during such an event.
Is there a cure for OTC deficiency?
Currently, there is no cure for OTC deficiency, but it is a manageable condition. Treatment focuses on preventing ammonia build-up through diet, medication, and close monitoring. In some severe cases, a liver transplant may be considered as it can provide a functional OTC enzyme.
How is OTC deficiency diagnosed in the UK?
Diagnosis often starts with blood tests for high ammonia levels and other metabolic markers. Confirmation usually involves genetic testing of the *OTC* gene, arranged through a clinical genetics service within the NHS Genomic Medicine Service. This testing helps identify the specific genetic changes causing the condition.
References
- Donovan K, Vaqar S, Guzman N. Ornithine Transcarbamylase Deficiency. 2024. PMID: 30725942
- Winchester S, Singh PK, Mikati MA. Ataxia. Handbook of clinical neurology. 2013. PMID: 23622331
- Knerr I, Cassiman D. Ornithine transcarbamylase deficiency: A diagnostic odyssey. Journal of inherited metabolic disease. 2022. PMID: 35734906
- Holzbach RT. Jaundice in pregnancy--1976. The American journal of medicine. 1976. PMID: 786010
- Feigenbaum A. Challenges of managing ornithine transcarbamylase deficiency in female heterozygotes. Molecular genetics and metabolism reports. 2022. PMID: 36620389
- Seker Yilmaz B, Baruteau J, Arslan N. Three-Country Snapshot of Ornithine Transcarbamylase Deficiency. Life (Basel, Switzerland). 2022. PMID: 36362876
- Seker Yilmaz B, Gissen P. Genetic Therapy Approaches for Ornithine Transcarbamylase Deficiency. Biomedicines. 2023. PMID: 37626723
- Nakajima H, Sasaki Y, Maeda T. Antepartum ornithine transcarbamylase deficiency. Case reports in gastroenterology. 2014. PMID: 25759629